Transcenta Holding Limited

Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacture, and commercialization of drugs for unmet medical needs in the People's Republic of China and the United States. Its pipeline includes TST001, a humanized claudin 18.2 monoclonal antibody candidate for solid tumors such as gastric and gastroesophageal cancer; TST808, a humanized antibody neutralizing APRIL and targeting B/plasma cells; TST002 (Blosozumab), a humanized sclerostin monoclonal antibody candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP-2) monoclonal antibody candidate for IgA kidney diseases. The company also develops TST106, a humanized bispecific antibody-based drug conjugate targeting CLDN18.2 and an undisclosed tumor antigen; TST198, targeting Claudin18.2 in solid tumors; TST786, a trispecific antibody targeting PD1, VEGF, and GREMLIN-1; TST013, an ADC targeting LIV-1 for breast cancer and other tumor types; TST003, a regulatory protein expressed by stromal and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; and TST105, a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor. It has research collaborations with Alebund Pharmaceuticals, Dana-Farber Cancer Institute, and John Hopkins University. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. It was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.